NO970625L - 17q-koblete bryst- og ovariekreft mottagelighetsgener - Google Patents

17q-koblete bryst- og ovariekreft mottagelighetsgener

Info

Publication number: NO970625L
Authority: NO; Norway
Prior art keywords: ovarian cancer; breast; human; mutations; gene
Prior art date: 1994-08-12

Application number

NO970625A

Other languages

English (en)

Norwegian (no)

Other versions

NO970625D0 (no

Inventor

Mark H Skolnick

David E Goldgar

Yoshio Miki

Jeff Swenson

Alexander Kamb

Keith D Harshman

Donna M Shattuck-Eidens

Sean V Tavtigian

Roger W Wiseman

Andrew P Futreal

Original Assignee

Myriad Genetics Inc

Us Health

Univ Utah Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-12

Filing date

1997-02-11

Publication date

1997-04-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27575337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970625(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-07 Priority claimed from US08/483,554 external-priority patent/US5747282A/en

1995-06-07 Priority claimed from US08/487,002 external-priority patent/US5710001A/en

1997-02-11 Application filed by Myriad Genetics Inc, Us Health, Univ Utah Res Found filed Critical Myriad Genetics Inc

1997-02-11 Publication of NO970625D0 publication Critical patent/NO970625D0/no

1997-04-14 Publication of NO970625L publication Critical patent/NO970625L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pathology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Medical Treatment And Welfare Office Work (AREA)
Apparatus For Radiation Diagnosis (AREA)

NO970625A 1994-08-12 1997-02-11 17q-koblete bryst- og ovariekreft mottagelighetsgener NO970625L (no)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US28922194A	1994-08-12	1994-08-12
US30026694A	1994-09-02	1994-09-02
US30810494A	1994-09-16	1994-09-16
US34882494A	1994-11-29	1994-11-29
US40930595A	1995-03-24	1995-03-24
US48801195A	1995-06-07	1995-06-07
US08/483,554 US5747282A (en)	1994-08-12	1995-06-07	17Q-linked breast and ovarian cancer susceptibility gene
US08/487,002 US5710001A (en)	1994-08-12	1995-06-07	17q-linked breast and ovarian cancer susceptibility gene
PCT/US1995/010203 WO1996005307A2 (en)	1994-08-12	1995-08-11	17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE

Publications (2)

Publication Number	Publication Date
NO970625D0 NO970625D0 (no)	1997-02-11
NO970625L true NO970625L (no)	1997-04-14

Family

ID=27575337

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO970625A NO970625L (no)	1994-08-12	1997-02-11	17q-koblete bryst- og ovariekreft mottagelighetsgener
NO970626A NO970626L (no)	1994-08-12	1997-02-11	Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO970626A NO970626L (no)	1994-08-12	1997-02-11	Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft

Country Status (15)

Country	Link
EP (2)	EP0705902B2 (pt)
JP (1)	JP3399539B2 (pt)
CN (1)	CN1159829A (pt)
AT (2)	ATE209660T1 (pt)
AU (2)	AU691958B2 (pt)
CA (2)	CA2196790C (pt)
DE (2)	DE69524182T3 (pt)
DK (2)	DK0699754T3 (pt)
ES (2)	ES2164136T5 (pt)
FI (2)	FI970514A7 (pt)
GR (1)	GR3035631T3 (pt)
NO (2)	NO970625L (pt)
NZ (1)	NZ291624A (pt)
PT (2)	PT699754E (pt)
WO (2)	WO1996005307A2 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995019369A1 (en)	1994-01-14	1995-07-20	Vanderbilt University	Method for detection and treatment of breast cancer
US6403303B1 (en) *	1996-05-14	2002-06-11	Visible Genetics Inc.	Method and reagents for testing for mutations in the BRCA1 gene
US6083698A (en) *	1995-09-25	2000-07-04	Oncormed, Inc.	Cancer susceptibility mutations of BRCA1
US5654155A (en) *	1996-02-12	1997-08-05	Oncormed, Inc.	Consensus sequence of the human BRCA1 gene
US6838256B2 (en)	1996-02-12	2005-01-04	Gene Logic Inc.	Coding sequences of the human BRCA1 gene
US6951721B2 (en)	1996-02-12	2005-10-04	Gene Logic Inc.	Method for determining the haplotype of a human BRCA1 gene
US6130322A (en) *	1996-02-12	2000-10-10	Gene Logic, Inc.	Coding sequences of the human BRCA1 gene
US5891857A (en) *	1996-02-20	1999-04-06	Vanderbilt University	Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
WO1998005968A1 (en)	1996-08-02	1998-02-12	The Wistar Institute Of Anatomy And Biology	Brca1 associated protein (bap-1) and uses therefor
WO1998012327A2 (en) *	1996-09-20	1998-03-26	Board Of Regents, The University Of Texas System	Compositions and methods comprising bard1 and other brca1 binding proteins
US6617104B2 (en)	1996-12-03	2003-09-09	Michael R. Swift	Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
US5965377A (en) *	1997-03-24	1999-10-12	Baystate Medical Center	Method for determining the presence of mutated BRCA protein
AU754748B2 (en) *	1997-06-04	2002-11-21	Rijksuniversiteit Te Leiden	A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
WO1999002559A1 (en) *	1997-07-07	1999-01-21	Abbott Laboratories	Reagents and methods useful for detecting diseases of the breast
US5994096A (en) *	1997-07-25	1999-11-30	Smithkline Beecham Corporation	Regulator
US6492109B1 (en)	1997-09-23	2002-12-10	Gene Logic, Inc.	Susceptibility mutation 6495delGC of BRCA2
US6177410B1 (en)	1997-12-05	2001-01-23	Vanderbilt University	Therapeutic methods for prostate cancer
US6686163B2 (en)	1998-05-06	2004-02-03	Gene Logic Inc.	Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
WO2002071928A2 (en) *	2001-03-14	2002-09-19	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
FR2836919B1 (fr) *	2002-03-05	2004-07-09	Centre Nat Rech Scient	Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
FR2826012B1 (fr) *	2001-06-13	2003-09-26	Centre Nat Rech Scient	Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
CA2450663A1 (fr) *	2001-06-13	2002-12-19	Centre National De La Recherche Scientifique (C.N.R.S.)	Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques
JP4500161B2 (ja)	2002-04-30	2010-07-14	クドスファーマシューティカルズリミテッド	フタラジノン誘導体
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
AU2004294790B2 (en)	2003-12-01	2010-03-11	Kudos Pharmaceuticals Limited	DNA damage repair inhibitors for treatment of cancer
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
CN101037690B (zh) *	2006-03-16	2011-07-20	国家人口计生委科学技术研究所	具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
CA2651995C (en)	2006-05-18	2017-04-25	Molecular Profiling Institute, Inc.	System and method for determining individualized medical intervention for a disease state
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
AU2007266840B2 (en)	2006-05-31	2012-09-20	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CA2674436C (en)	2007-01-10	2012-07-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
GB0716532D0 (en)	2007-08-24	2007-10-03	Angeletti P Ist Richerche Bio	Therapeutic compounds
JP2010539149A (ja)	2007-09-14	2010-12-16	アストラゼネカアクチボラグ	フタラジノン誘導体
MX2010004028A (es)	2007-10-17	2010-04-30	Kudos Pharm Ltd	4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US8012976B2 (en)	2008-08-06	2011-09-06	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
KR101649541B1 (ko)	2008-08-10	2016-08-19	쿠아키니 메디컬 센터	건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법
PT2346495T (pt)	2008-10-07	2016-11-11	Astrazeneca Uk Ltd	Formulação farmacêutica 514
WO2011109440A1 (en)	2010-03-01	2011-09-09	Caris Life Sciences Luxembourg Holdings	Biomarkers for theranostics
CN107254538A (zh)	2008-11-12	2017-10-17	卡里斯生命科学瑞士控股有限责任公司	使用外来体来确定表现型的方法和系统
EP2393939B1 (en) *	2009-02-06	2014-09-17	Yale University	A snp marker of breast and ovarian cancer risk
AR079774A1 (es)	2009-07-15	2012-02-22	Astrazeneca Ab	Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo
US9469876B2 (en)	2010-04-06	2016-10-18	Caris Life Sciences Switzerland Holdings Gmbh	Circulating biomarkers for metastatic prostate cancer
CN105525009B (zh) *	2016-01-26	2018-10-16	绍兴华因生物科技有限公司	检测杂合性brca1/2基因缺失的方法及所用引物
MX2020012066A (es)	2018-05-14	2021-04-28	Nuvation Bio Inc	Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
WO2020232119A1 (en)	2019-05-14	2020-11-19	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
MA57972B1 (fr)	2019-07-19	2025-05-30	Astrazeneca Ab	Inhibiteurs de parp1
EP4058464A1 (en)	2019-11-13	2022-09-21	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
CN113388680B (zh) *	2020-03-14	2023-07-04	复旦大学附属妇产科医院	上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
KR102262529B1 (ko) *	2020-06-15	2021-06-09	연세대학교 산학협력단	Brca 변이성 난소암에 대한 진단 방법 및 이를 이용한 키트
US11795158B2 (en)	2020-06-25	2023-10-24	Astrazeneca Ab	Chemical compounds
CN116348115A (zh)	2020-10-09	2023-06-27	阿斯利康(英国)有限公司	抗体-药物缀合物和parp1选择性抑制剂的组合
JP2024510792A (ja)	2021-03-23	2024-03-11	ニューベイション・バイオ・インコーポレイテッド	抗がん核内ホルモン受容体標的化化合物
US12006314B2 (en)	2021-05-03	2024-06-11	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
US20240366584A1 (en)	2021-06-21	2024-11-07	Tesaro, Inc.	Combination treatment of cancer with a parp inhibitor and a lipophilic statin
US20250025568A1 (en)	2021-11-18	2025-01-23	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and parp1 selective inhibitor
CN118317793A (zh)	2021-12-21	2024-07-09	阿斯利康(瑞典)有限公司	治疗脑肿瘤和神经母细胞瘤的方法
KR20240130087A (ko)	2021-12-28	2024-08-28	아스트라제네카 유케이 리미티드	항체-약물 접합체와 atr 저해제의 조합
CN118434422A (zh)	2021-12-28	2024-08-02	阿斯利康(英国)有限公司	抗体-药物缀合物和rasg12c抑制剂的组合
KR20240165390A (ko)	2022-03-16	2024-11-22	아스트라제네카 유케이 리미티드	항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
US20250213556A1 (en)	2022-04-07	2025-07-03	Astrazeneca Ab	Combination therapy for treating cancer
KR20240170958A (ko)	2022-04-07	2024-12-05	아스트라제네카 아베	암 치료를 위한 병용 요법
US20250235448A1 (en)	2022-04-07	2025-07-24	Astrazeneca Ab	Combination therapy for treating cancer
AU2023290506A1 (en)	2022-06-15	2025-01-23	Astrazeneca Ab	Combination therapy for treating cancer
US20250360222A1 (en)	2022-07-28	2025-11-27	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024116094A1 (en)	2022-11-30	2024-06-06	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugates and dnmt inhibitors
WO2025088496A1 (en)	2023-10-24	2025-05-01	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2025120513A1 (en)	2023-12-05	2025-06-12	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2025153668A1 (en)	2024-01-19	2025-07-24	Astrazeneca Ab	Pharmaceutical compositions comprising azd5305

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4486530A (en)	1980-08-04	1984-12-04	Hybritech Incorporated	Immunometric assays using monoclonal antibodies
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
CA1188246A (en)	1981-08-31	1985-06-04	Jerry L. Gregory	Immobilized microbe recycle apparatus
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4868105A (en)	1985-12-11	1989-09-19	Chiron Corporation	Solution phase nucleic acid sandwich assay
IE61148B1 (en)	1988-03-10	1994-10-05	Ici Plc	Method of detecting nucleotide sequences
US5362623A (en) *	1991-06-14	1994-11-08	The John Hopkins University	Sequence specific DNA binding by p53
ES2115611T3 (es) *	1990-01-04	1998-07-01	Univ Johns Hopkins	Gen suprimido en el cancer colorrectal humano.
ES2264239T3 (es) *	1990-06-27	2006-12-16	Princeton University	Complejo de proteinas p53/p90'.
AU1236092A (en) *	1991-01-04	1992-08-17	Baylor College Of Medicine	Tumor susceptible non-human animals
IL103059A0 (en)	1991-09-30	1993-02-21	Boehringer Ingelheim Int	Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
WO1994000764A1 (en) *	1992-06-26	1994-01-06	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES	The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) *	1994-01-14	1995-07-20	Vanderbilt University	Method for detection and treatment of breast cancer

1995
- 1995-08-11 ES ES95305601T patent/ES2164136T5/es not_active Expired - Lifetime
- 1995-08-11 WO PCT/US1995/010203 patent/WO1996005307A2/en not_active Ceased
- 1995-08-11 PT PT95305602T patent/PT699754E/pt unknown
- 1995-08-11 DK DK95305602T patent/DK0699754T3/da active
- 1995-08-11 NZ NZ291624A patent/NZ291624A/en not_active IP Right Cessation
- 1995-08-11 AT AT95305601T patent/ATE209660T1/de not_active IP Right Cessation
- 1995-08-11 CA CA002196790A patent/CA2196790C/en not_active Expired - Lifetime
- 1995-08-11 EP EP95305601A patent/EP0705902B2/en not_active Expired - Lifetime
- 1995-08-11 AU AU32428/95A patent/AU691958B2/en not_active Expired
- 1995-08-11 WO PCT/US1995/010220 patent/WO1996005308A1/en not_active Ceased
- 1995-08-11 PT PT95305601T patent/PT705902E/pt unknown
- 1995-08-11 EP EP95305602A patent/EP0699754B2/en not_active Expired - Lifetime
- 1995-08-11 AU AU33216/95A patent/AU691331B2/en not_active Expired
- 1995-08-11 CN CN95195311.7A patent/CN1159829A/zh active Pending
- 1995-08-11 DE DE69524182T patent/DE69524182T3/de not_active Expired - Lifetime
- 1995-08-11 DK DK95305601T patent/DK0705902T3/da active
- 1995-08-11 AT AT95305602T patent/ATE198623T1/de not_active IP Right Cessation
- 1995-08-11 CA CA002196795A patent/CA2196795C/en not_active Expired - Lifetime
- 1995-08-11 ES ES95305602T patent/ES2154712T5/es not_active Expired - Lifetime
- 1995-08-11 DE DE69519834T patent/DE69519834T3/de not_active Expired - Lifetime
- 1995-08-11 JP JP50751696A patent/JP3399539B2/ja not_active Expired - Lifetime
1997
- 1997-02-07 FI FI970514A patent/FI970514A7/fi not_active IP Right Cessation
- 1997-02-07 FI FI970515A patent/FI970515A7/fi unknown
- 1997-02-11 NO NO970625A patent/NO970625L/no not_active Application Discontinuation
- 1997-02-11 NO NO970626A patent/NO970626L/no not_active Application Discontinuation
2001
- 2001-03-23 GR GR20010400476T patent/GR3035631T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO970626L (no)	1997-04-14
DE69524182T2 (de)	2002-05-29
EP0705902B2 (en)	2008-08-06
CA2196795C (en)	2001-04-03
ES2164136T3 (es)	2002-02-16
CN1159829A (zh)	1997-09-17
GR3035631T3 (en)	2001-06-29
WO1996005308A1 (en)	1996-02-22
EP0705902A1 (en)	1996-04-10
EP0699754B1 (en)	2001-01-10
ES2154712T5 (es)	2009-12-14
AU3321695A (en)	1996-03-07
CA2196795A1 (en)	1996-02-22
CA2196790A1 (en)	1996-02-22
DK0705902T3 (da)	2002-03-11
EP0699754B2 (en)	2009-08-12
DE69519834D1 (de)	2001-02-15
ES2164136T5 (es)	2009-02-16
NZ291624A (en)	1998-07-28
AU691331B2 (en)	1998-05-14
AU3242895A (en)	1996-03-07
DE69519834T3 (de)	2010-04-01
ATE198623T1 (de)	2001-01-15
DE69524182T3 (de)	2009-07-09
EP0699754A1 (en)	1996-03-06
JP3399539B2 (ja)	2003-04-21
NO970625D0 (no)	1997-02-11
WO1996005307A3 (en)	1996-03-14
AU691958B2 (en)	1998-05-28
ATE209660T1 (de)	2001-12-15
WO1996005307A2 (en)	1996-02-22
FI970515A7 (fi)	1997-04-07
EP0705902B1 (en)	2001-11-28
FI970514A7 (fi)	1997-04-07
NO970626D0 (no)	1997-02-11
DE69519834T2 (de)	2001-04-26
DE69524182D1 (de)	2002-01-10
PT699754E (pt)	2001-04-30
DK0699754T3 (da)	2001-02-26
JP2002502227A (ja)	2002-01-22
FI970515A0 (fi)	1997-02-07
PT705902E (pt)	2002-05-31
ES2154712T3 (es)	2001-04-16
CA2196790C (en)	2000-10-10
FI970514A0 (fi)	1997-02-07

Publication	Publication Date	Title
NO970625L (no)	1997-04-14	17q-koblete bryst- og ovariekreft mottagelighetsgener
NO970624L (no)	1997-04-14	In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener
NO982785L (no)	1998-08-17	Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (en)	2002-12-04	Chromosome 13-linked breast cancer susceptibility gene
EP0756488A4 (en)	1997-07-02	TUMOR SUPPRESSOR GENE AND METHOD FOR DETECTING CANCER
Truderung et al.	2021	Melanoma susceptibility: An update on genetic and epigenetic findings
Alimirzaie et al.	2018	Mutations in known and novel cancer susceptibility genes in young patients with pancreatic cancer
Bijlsma et al.	1997	Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.
Martin et al.	2002	Exclusion of PITX2 mutations as a major cause of CHARGE association
Wang et al.	2016	Braf mutations initiate the development of rat gliomas induced by postnatal exposure to N-Ethyl-N-nitrosourea
Wu et al.	1998	Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.
Wan et al.	2004	Two variants of the human hepatocellular carcinoma‐associated HCAP1 gene and their effect on the growth of the human liver cancer cell line Hep3B
Venkateshwari et al.	2017	BRIP1/FANCJ mutation analysis in a family with history of male and female breast Cancer in India
Nilbert et al.	2000	Novel germline APC mutations in Swedish patients with familial adenomatous polyposis and Gardner syndrome
Tell-Marti et al.	2017	The p. R151c polymorphism in mc1r gene modifies the age of onset in spanish huntington’s disease patients
Feng et al.	2002	Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2‐related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families
Espinós et al.	1998	Ala397Asp mutation of myosin VIIA gene segregating in a Spanish family with type-Ib Usher syndrome
Vile	1993	p53: a gene for all tumours?
WO2001085911A3 (en)	2002-05-23	Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
MX9701076A (es)	1998-02-28	Metodo para diagnosticar una predisposicion para cancer de pecho y ovario.
Bale et al.	2001	Cancer-associated genodermatoses and familial cancer syndromes with cutaneous manifestations
Lebhard	2019	The effects of SNP285 and SNP309 on the expression of MDM2 and p53 in breast cancer.

Legal Events

Date	Code	Title	Description
2003-04-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application